Long-term Impact of NMDAR Encephalitis, Level 3

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospices Civils de Lyon

About this trial

NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored.

Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.

Eligibility criteria

Qualifiers

Patients with NMDAR encephalitis

Age ≥ 18 years old

Patient affiliated to a social security system

No opposition from the patient

Disqualifiers

Patients whithout NMDAR encephalitis

Patient under guardianship or curatorship

Patient with neurological disorders pre-existing encephalitis

Trial design

Treatments tested in this trial

  • Questionnaires

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators

Hospices Civils de Lyon

Lead sponsor

Charite University, Berlin, Germany

Collaborator